Primary sclerosing cholangitis: Conventional and quantitative liver function tests during long-term therapy with ursodeoxycholic acid;PRIMAR SKLEROSIERENDE CHOLANGITIS: KONVENTIONELLE UND QUANTITATIVE LEBERFUNKTIONSTESTS UNTER EINER MEHRJAHRIGEN THERAPIE MIT URSODESOXYCHOLSAURE

Zeitschrift fur Gastroenterologie

Volumn 34, Issue 2, 1996, Pages 123-127

  V Schonfeld J ^a   Zotz, R ^a   Mahl, M ^a   Beste, M ^a   Breuer, N ^a   Goebell, H ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

liver function tests; primary sclerosing cholangitis; ursodeoxycholic acid

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; ENDOGENOUS COMPOUND; GAMMA GLUTAMYLTRANSFERASE; PROTEIN; URSODEOXYCHOLIC ACID; CHOLAGOGUE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LIVER FUNCTION; MALE; PRIMARY SCLEROSING CHOLANGITIS; BLOOD; FOLLOW UP; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; LONG TERM CARE; MIDDLE AGED; PHYSIOLOGY; SCLEROSING CHOLANGITIS; TREATMENT OUTCOME;

ADULT; BILIRUBIN; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; LONG-TERM CARE; MALE; MIDDLE AGED; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 13344282069     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Farrant JM, Hayllar KM, Wilkinson ML et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991; 100: 1710-7
2. La Russo NF, Wiesner RH, Ludwig J et al. Primary sclerosing cholangitis. N Engl J Med 1984; 310: 899-903
3. Olsson R, Danielsson A, Jarnerot G et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991; 100: 1319-23
4. Chapman RWG, Arborgh BAM, Rhodes JM et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography and hepatic histology. Gut 1980; 21: 870-7
5. Porayko MK, Wiesner RH, La Russo NF et al. Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. Gastroenterology 1990; 98: 1594-1602
6. Wiesner RH, Grambsch PM, Dickson ER et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989, 10: 430-6
7. Stiehl A, Walker S, Stiehl L et al. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 1994; 20: 57-64
8. Wiesner RH. Advances in therapy for primary sclerosing cholangitits. Eur J Gastroenterol Hepatol 1992; 4: 276-83
9. Beuers U, Spengler U, Kruis W et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992; 16: 707-14
10. Van Tiel DH, Wright HI, Gavaler JS. Ursodeoxycholic acid (UDCA) therapy for primary sclerosing cholangitis (PSC): preliminary report of a randomized controlled trial. Hepatology 1992; 16: 62A
11. Lo SK, Herrmann R, Chapman RW et al. Ursodeoxycholic acid in primary sclerosing cholangitis: a double-blind placebo controlled trial. Hepatology 1992; 16: 92A
12. O'Brien CB, Senior JR, Arora-Mirchandani R et al. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology 1991; 14: 838-47
13. Chazouilleres O, Poupon R, Capron JP et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 1990; 11: 120-3
14. Albers I, Hartmann H, Bircher J et al. Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol 1989; 24: 269-76
15. Clements D, Elias E, McMaster P. Preliminary study of indocyanine green clearance in primary biliary cirrhosis. Scand J Gastroenterol 1991; 26: 119-23
16. Merkel C, Gatta A, Zoli M et al. Prognostic value of galactose elimination capacity, aminopyrine breath test and ICG clearance in patients with cirrhosis. Dig Dis Sci 1991; 36: 1197-1203
17. Reichen J, Widmer T, Cotting J. Accurate prediction of death by serial determination of galactose elimination capacity in primary biliary cirrhosis, a comparison with the Mayo model. Hepatology 1991; 14: 504-10
18. Meijer DKF, Weert B, Vermeer GA. Pharmacokinetics of biliary excretion in man. VI. Indocyanine green. Eur J Clin Pharmacol 1988; 35: 295-303
19. Lermann A, Hildebrand FL, Margulies KB et al. Endothelin: a new cardiovascular regulatory peptide. Mayo Clinic Proc 1990; 65: 1441-55
20. Tygstrup N. Determination of the hepatic elimination capacity of galactose by single injection. Scand J Clin Lab Invest 1966; 92 (suppl. 18): 118-25
21. Leuschner U, Güldütuna S, Imhof M et al. Effects of ursodeoxycholic acid after 4 to 12 years of therapy in early and late stages of primary biliary cirrhosis. J Hepatol 1994; 21: 624-33